Cancer genomics and its role in human cancers
Journal of Proteomics & Bioinformatics

Journal of Proteomics & Bioinformatics
Open Access

ISSN: 0974-276X

Cancer genomics and its role in human cancers

Joint Event on 9th World Biomarkers Congress & 20th International Conference on Pharmaceutical Biotechnology

December 07-09, 2017 | Madrid, Spain

Jianhua Luo

University of Pittsburgh School of Medicine, USA

Keynote: J Proteomics Bioinform

Abstract :

Cancer remains one of the most lethal diseases for human. In recent studies, we performed whole genome analysis on prostate and liver cancers. Our result showed that combination of genome copy number variance, genome methylation pattern and novel fusion transcripts specific for cancer achieved high accuracy in predicting clinical outcomes of these cancers. Interestingly, some of these fusion genes are also present in a variety of human malignancies. Some of these fusion gene products trigger new pathways that are essential for carcinogenesis in multiple human cancers, and create novel functions that are not present in wild type gene counterparts. Some of these novel fusion genes are highly targetable and treatment of cancers with drugs specific for these genes and their signaling pathways produced dramatic improvement of metastasis and survival rate of animals xenografted with cancers positive for these fusion genes. Our analyses suggest that targeting therapy for fusion genes holds promise as an effective treatment for human cancers.

Biography :

Jianhua Luo has been studying molecular mechanism related to human malignancies in the last 24 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 16 years, he has been largely focusing on genetic and molecular mechanism of human prostate cancer and hepatocellular carcinomas. He has characterized several signaling pathways that play critical role in prostate cancer development. He proposed prostate cancer field effect in 2002 and he is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, his group found that patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. His discovery of several novel fusion transcripts and their association with aggressive prostate cancer has brought significant new insight into the field of prostate cancer research. Overall, these findings advance our understanding on how cancer develops and behaves and lay down the foundation for better future diagnosis and treatment of human malignancies.